The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global onychomycosis treatment market reached a value of US$ 2.94 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.12 Billion by 2027, exhibiting at a CAGR of 5.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can lead to discomfort, chronic pain and disfigurement. Proximal subungual, white superficial and distal subungual are some of the types of onychomycosis. It is a common nail infection in patients with athlete’s foot and is caused by various organisms, such as dermatophytes, yeasts and non-dermatophyte molds. Onychomycosis is characterized by symptoms, including distortion in the shape of nails, foul smell, whitish to yellow-brown discoloration and brittle, ragged and crumbly texture of the nails. It is usually diagnosed through potassium, oxygen and hydrogen (KOH) examination, culture and histopathological examinations of nail clippings and nail biopsies and is treated through laser therapy, drugs and photodynamic therapies.
The increasing prevalence of chronic medical ailments, such as onychomycosis, human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is highly prone to circulatory disorders and weakened immune system, is providing a thrust to the market growth. Onychomycosis is also highly prevalent among millennials and adults due to the increased exposure to public swimming pools and utilization of tight, contaminated or soiled clothes, shoes and socks. Additionally, the development of water-soluble antifungal treatment solutions that can be administered orally is providing a thrust to the market growth. They aid in preventing secondary bacterial infections and prevent the growth of fungus. Other factors, including the widespread utilization of topical nail lacquers and ointments to maintain nail hygiene, along with the significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global onychomycosis treatment market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on disease type, treatment type, drug class and distribution channel.
Breakup by Disease Type:
Breakup by Treatment Type:
Breakup by Drug Class:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc. and The OTC Lab B.V.
|Base Year of the Analysis||2021|
|Segment Coverage||Disease Type, Treatment Type, Drug Class, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc. and The OTC Lab B.V.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global onychomycosis treatment market was valued at US$ 2.94 Billion in 2021.
We expect the global onychomycosis treatment market to exhibit a CAGR of 5.50% during 2022-2027.
The high prevalence of onychomycosis among the masses, along with the advent of water-soluble antifungal treatment solutions, is primarily driving the global onychomycosis treatment market.
The sudden outbreak of the COVID-19 pandemic has led to the rising inclination towards e-pharmacy solutions that administer the onychomycosis treatment via providing topical nail lacquers and ointments to maintain nail hygiene.
Based on the disease type, the global onychomycosis treatment market can be categorized into distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis, candidal onychomycosis, and others. Among these, distal subungual onychomycosis holds the majority of the total market share.
Based on the treatment type, the global onychomycosis treatment market has been segmented into laser therapy, photodynamic therapy, and drug treatment. Currently, drug treatment represents the largest market share.
Based on the distribution channel, the global onychomycosis treatment market can be bifurcated into hospitals and clinics, online stores, retail pharmacies, and others. Among these, retail pharmacies account for the majority of the total market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global onychomycosis treatment market include Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc., and The OTC Lab B.V.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at